Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2013 | Original Article

Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis

Authors: Motoho Morita, Tetsuya Higuchi, Arifudin Achmad, Azusa Tokue, Yukiko Arisaka, Yoshito Tsushima

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2013

Abstract

Purpose

The usefulness of ¹⁸F-FDG PET/CT for bone metastasis evaluation has already been established. The amino acid PET tracer [¹⁸F]-3-fluoro-alpha-methyl tyrosine (¹⁸F-FAMT) has been reported to be highly specific for malignancy. We evaluated the additional value of ¹⁸F-FAMT PET/CT to complement ¹⁸F-FDG PET/CT in the evaluation of bone metastasis.

Methods

This retrospective study included 21 patients with bone metastases of various cancers who had undergone both ¹⁸F-FDG and ¹⁸F-FAMT PET/CT within 1 month of each other. ¹⁸F-FDG-avid bone lesions suspicious for malignancy were carefully selected based on the cut-off value for malignancy, and the SUVmax of the ¹⁸F-FAMT in the corresponding lesions were evaluated.

Results

A total of 72 ¹⁸F-FDG-positive bone lesions suspected to be metastases in the 21 patients were used as the reference standard. ¹⁸F-FAMT uptake was found in 87.5 % of the lesions. In the lesions of lung cancer origin, the uptake of the two tracers showed a good correlation (40 lesions, r = 0.68, P < 0.01). Bone metastatic lesions of oesophageal cancer showed the highest average of ¹⁸F-FAMT uptake. Bone metastatic lesions of squamous cell carcinoma showed higher ¹⁸F-FAMT uptake than those of adenocarcinoma. No significant difference in ¹⁸F-FAMT uptake was seen between osteoblastic and osteolytic bone metastatic lesions.

Conclusion

The usefulness of ¹⁸F-FAMT PET/CT for bone metastasis detection regardless of the lesion phenotype was demonstrated. The fact that ¹⁸F-FAMT uptake was confirmed by ¹⁸F-FDG uptake suggests that ¹⁸F-FAMT PET/CT has the potential to complement ¹⁸F-FDG PET/CT for the detection of bone metastases.

Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801. doi:10.1016/S1470-2045(12)70211-5.PubMedCrossRef

Mackiewicz-Wysocka M, Pankowska M, Wysocki PJ. Progress in the treatment of bone metastases in cancer patients. Expert Opin Investig Drugs. 2012;21(6):785–95. doi:10.1517/13543784.2012.679928.PubMedCrossRef

Yu HH, Tsai YY, Hoffe SE. Overview of diagnosis and management of metastatic disease to bone. Cancer Control. 2012;19(2):84–91.PubMed

Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging. 2011;55(4):374–410.PubMed

Murtz P, Krautmacher C, Traber F, Gieseke J, Schild HH, Willinek WA. Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla. Eur Radiol. 2007;17(12):3031–7.PubMedCrossRef

Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287–97.PubMed

Schirrmeister H, Buck A, Guhlmann A, Reske SN. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid. 2001;11(7):677–83. doi:10.1089/105072501750362754.PubMedCrossRef

Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42(12):1800–4.PubMed

Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40(10):1623–9.PubMed

10.

Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol. 2001;177(1):229–36.PubMedCrossRef

11.

Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49(1):68–78. doi:10.2967/jnumed.106.037200.PubMedCrossRef

12.

Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med. 2005;19(7):573–9. doi:10.1007/Bf02985050.PubMedCrossRef

13.

Kong F-L, Yang DJ. Amino acid transporter-targeted radiotracers for molecular imaging in oncology. Curr Med Chem. 2012;19(20):3271–81. doi:10.2174/092986712801215946.PubMedCrossRef

14.

Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70(1):43–77.PubMed

15.

McGivan JD, Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochem J. 1994;299(Pt 2):321–34.PubMed

16.

Oxender DL, Christensen HN. Evidence for two types of mediation of neutral and amino-acid transport in Ehrlich cells. Nature. 1963;197:765–7.PubMedCrossRef

17.

Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273(37):23629–32.PubMedCrossRef

18.

Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514(2):291–302.PubMedCrossRef

19.

Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 2006;119(3):484–92. doi:10.1002/Ijc.21866.PubMedCrossRef

20.

Goudarzi B, Kishimoto R, Komatsu S, Ishikawa H, Yoshikawa K, Kandatsu S, et al. Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with C-11-methionine PET and bone scintigraphy. Magn Reson Imaging. 2010;28(3):372–9. doi:10.1016/j.mri.2009.12.008.PubMedCrossRef

21.

Tomiyoshi K, Amed K, Muhammad S, Higuchi T, Inoue T, Endo K, et al. Synthesis of isomers of F-18-labelled amino acid radiopharmaceutical: position 2- and 3-L-F-18-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18(2):169–75. doi:10.1097/00006231-199702000-00013.PubMedCrossRef

22.

Inoue T, Tomiyoshi K, Higuichi T, Ahmed K, Sarwar M, Aoyagi K, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med. 1998;39(4):663–7.PubMed

23.

Inoue T, Shibasaki T, Oriuchi N, Aoyagi K, Tomiyoshi K, Amano S, et al. 18F-alpha-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40(3):399–405.PubMed

24.

Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, et al. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci. 2009;100(4):753–8. doi:10.1111/j.1349-7006.2008.01077.x.PubMedCrossRef

25.

Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, et al. Diagnosis of maxillofacial tumor with L-3-[F-18]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med. 2007;21(2):129–35.PubMedCrossRef

26.

Miyashita G, Higuchi T, Oriuchi N, Arisaka Y, Hanaoka H, Tominaga H, et al. 18F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with 18F-FDG PET and immunohistochemistry. Ann Nucl Med. 2010;24(8):579–84. doi:10.1007/s12149-010-0398-2.PubMedCrossRef

27.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer. 2009;66(1):120–6. doi:10.1016/j.lungcan.2008.12.015.PubMedCrossRef

28.

Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13(21):6369–78. doi:10.1158/1078-0432.Ccr-07-1294.PubMedCrossRef

29.

Sato N, Inoue T, Tomiyoshi K, Aoki J, Oriuchi N, Takahashi A, et al. Gliomatosis cerebri evaluated by F-18 alpha-methyl tyrosine positron-emission tomography. Neuroradiology. 2003;45(10):700–7. doi:10.1007/s00234-003-1057-2.PubMedCrossRef

30.

Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG – preliminary study. Radiology. 2001;220(1):54–62.PubMed

31.

Watanabe H, Inoue T, Shinozaki T, Yanagawa T, Ahmed AR, Tomiyoshi K, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med Mol Imaging. 2000;27(10):1509–17. doi:10.1007/s002590000344.CrossRef

32.

Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, et al. Transport of 3-fluoro-L-alpha-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med. 2012;53(8):1253–61. doi:10.2967/jnumed.112.103069.PubMedCrossRef

33.

Watanabe H, Shinozaki T, Yanagawa T, Aoki J, Tokunaga M, Inoue T, et al. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br. 2000;82(5):760–7.PubMedCrossRef

34.

Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K, et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med. 2006;20(6):399–408.PubMedCrossRef

35.

Rosen RS, Fayad L, Wahl RL. Increased F-18-FDG uptake in degenerative disease of the spine: characterization with F-18-FDG PET/CT. J Nucl Med. 2006;47(8):1274–80.PubMed

36.

Costelloe CM, Murphy WA, Chasen BA. Musculoskeletal pitfalls in F-18-FDG PET/CT: pictorial review. AJR Am J Roentgenol. 2009;193(3):S25–30. doi:10.2214/Ajr.07.7138.

37.

Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22(14):2942–53. doi:10.1200/jco.2004.08.181.PubMedCrossRef

38.

Qu XH, Huang XL, Yan WL, Wu LM, Dai KR. A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81(5):1007–15. doi:10.1016/j.ejrad.2011.01.126.PubMedCrossRef

39.

Stecco A, Lombardi M, Leva L, Brambilla M, Negru E, Delli Passeri S, et al. Diagnostic accuracy and agreement between whole-body diffusion MRI and bone scintigraphy in detecting bone metastases. Radiol Med. 2013;118(3):165–75. doi:10.1007/s11547-012-0870-2.

40.

Hsu W, Hearty TM. Radionuclide imaging in the diagnosis and management of orthopaedic disease. J Am Acad Orthop Surg. 2012;20(3):151–9. doi:10.5435/JAAOS-20-03-151.PubMedCrossRef

41.

Ghanem N, Uhl M, Brink I, Schafer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55(1):41–55. doi:10.1016/j.ejrad.2005.01.016.PubMedCrossRef

42.

Peng X, Guo W, Ren T, Lou Z, Lu X, Zhang S, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One. 2013;8(3):e58361. doi:10.1371/journal.pone.0058361.PubMedCrossRef

43.

Chatterjee S, Frew J, Mott J, McCallum H, Stevenson P, Maxwell R, et al. Variation in radiotherapy target volume definition, dose to organs at risk and clinical target volumes using anatomic (computed tomography) versus combined anatomic and molecular imaging (positron emission tomography/computed tomography): intensity-modulated radiotherapy delivered using a tomotherapy Hi Art machine: final results of the VortigERN study. Clin Oncol (R Coll Radiol). 2012;24(10):e173–9. doi:10.1016/j.clon.2012.09.004.PubMedCrossRef

44.

Lucas JD, O’Doherty MJ, Wong JCH, Bingham JB, McKee PH, Fletcher CDM, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br. 1998;80(3):441–7. doi:10.1302/0301-620x.80b3.8232.PubMedCrossRef

Title: Complementary roles of tumour specific PET tracer 18F-FAMT to 18F-FDG PET/CT for the assessment of bone metastasis
Authors: Motoho Morita
Tetsuya Higuchi
Arifudin Achmad
Azusa Tokue
Yukiko Arisaka
Yoshito Tsushima
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2487-7

At a glance: The STEP trials

Springer Medicine

Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2013

Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery

Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis

A prospective analysis of 18F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features

Freehand SPECT for image-guided sentinel lymph node biopsy in breast cancer

Positron emission tomography based in-vivo imaging of early phase stem cell retention after intramyocardial delivery in the mouse model

Effect of emaciation and obesity on small-animal internal radiation dosimetry for positron-emitting radionuclides